BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
580
Employees580
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
580
Employees580

BCRX Key Statistics

Market cap
1.40B
Market cap1.40B
Price-Earnings ratio
-140.80
Price-Earnings ratio-140.80
Dividend yield
Dividend yield
Average volume
5.62M
Average volume5.62M
High today
$7.17
High today$7.17
Low today
$6.58
Low today$6.58
Open price
$7.12
Open price$7.12
Volume
6.71M
Volume6.71M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

The current BioCryst(BCRX) stock price is $6.70, with a market capitalization of 1.4B. The stock trades at a price-to-earnings (P/E) ratio of -140.80.

As of 2026-01-17, BioCryst(BCRX) stock has fluctuated between $6.58 and $7.17. The current price stands at $6.70, placing the stock +1.9% above today's low and -6.6% off the high.

The BioCryst(BCRX)'s current trading volume is 6.71M, compared to an average daily volume of 5.62M.

In the last year, BioCryst(BCRX) shares hit a 52-week high of $11.31 and a 52-week low of $6.00.

In the last year, BioCryst(BCRX) shares hit a 52-week high of $11.31 and a 52-week low of $6.00.

BCRX News

Simply Wall St 14h
A Look At BioCryst Pharmaceuticals Valuation After Its New 2026 Revenue Guidance

BioCryst Pharmaceuticals (BCRX) recently issued full year 2026 earnings guidance, telling investors it expects total revenue between US$635 million and US$660 m...

A Look At BioCryst Pharmaceuticals Valuation After Its New 2026 Revenue Guidance
TipRanks 5d
BioCryst: Sustained Orladeyo Momentum, Disciplined Financials, and Pipeline Upside Support Buy Rating

Serge Belanger, an analyst from Needham, maintained the Buy rating on BioCryst. The associated price target remains the same with $18.00. Claim 70% Off TipRanks...

TipRanks 5d
BioCryst Updates ORLADEYO Revenue Outlook and Guidance

Claim 70% Off TipRanks Premium BioCryst ( (BCRX) ) has issued an announcement. On January 12, 2026, BioCryst Pharmaceuticals reported that preliminary, unaudi...

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .